Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market to Reach $4.59 Billion by 2029, Growing at a CAGR of 29.7%
Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Industry In 2025?
The artificial intelligence (AI)-driven rare disease patient finder market has experienced significant expansion in recent years. It is projected to increase from $1.25 billion in 2024 to $1.62 billion in 2025, achieving a compound annual growth rate (CAGR) of 30.1%. This historical rise can be ascribed to several factors, including the expanded application of genomic sequencing, the growing acceptance of electronic health records, enhanced collaborations between pharmaceutical companies and AI startups, a heightened emphasis on early disease detection, and the increasing accessibility of real-world evidence.
The market for artificial intelligence (AI)-driven rare disease patient finders is projected to experience substantial expansion in the coming years, reaching $4.60 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 29.7%. This anticipated expansion throughout the forecast period stems from several factors, including the greater integration of multimodal data analytics, the increased use of AI-powered clinical decision support systems, the expanding deployment of wearable and remote monitoring devices, higher investment in patient-centric healthcare platforms, and an intensified focus on predictive analytics for identifying rare diseases. Key trends anticipated during this period encompass progress in natural language processing for managing unstructured medical data, the incorporation of federated learning for protected patient data sharing, multiomics data analysis facilitated by technology, new developments in generating synthetic data for rare disease modeling, and improvements in artificial intelligence (AI)-driven digital biomarkers.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28129&type=smp
What Are The Emerging Market Drivers Creating New Opportunities In The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Industry?
The expanding adoption of digital health and telemedicine is projected to fuel the growth of the artificial intelligence (AI)-driven rare disease patient finder market. Digital health encompasses the application of technology, software, and electronic tools to track, manage, and enhance overall health and wellness. Telemedicine, conversely, involves delivering healthcare services remotely through telecommunications technology, such as video conferences, mobile applications, and online platforms. The increasing embrace of digital health and telemedicine is attributed to patients and providers seeking convenient, efficient, and accessible healthcare alternatives. The artificial intelligence (AI)-driven rare disease patient finder supports both digital health and telemedicine by accurately identifying patients, enabling remote oversight, facilitating timely virtual consultations, and providing personalized care. As an illustration, a survey conducted by Rock Health, a US-based health technology company, in February 2023 revealed that out of 8,014 respondents, 76% of individuals over the age of 55 had used telemedicine, and 80% of all respondents indicated they had accessed care via telemedicine at some point in their lives, marking an 8% rise from 72% in 2021. Therefore, the growing acceptance of digital health and telemedicine serves as a significant driver for the artificial intelligence (AI)-driven rare disease patient finder market.
How Is The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Classified Into Different Segments?
The artificial intelligence (AI)-driven rare disease patient finder market covered in this report is segmented as
1) By Component: Software, Services
2) By Deployment Mode: Cloud-Based, On-Premises
3) By Application: Hospitals, Clinics, Research Institutes, Pharmaceutical Companies, Other Applications
4) By End-User: Healthcare Providers, Life Sciences Companies, Payers, Other End-Users
Subsegments:
1) By Software: Electronic Data Capture, Data Management Platform, Analytics And Reporting Tools, Patient Engagement Tools, Clinical Trial Management System
2) By Services: Implementation And Integration, Training And Support, Data Hosting And Security, Consulting Services, Maintenance And Upgrades
What Are The Latest Industry Trends Transforming The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
Major companies operating in the AI-driven rare disease patient finder market are primarily focused on developing technological innovations, such as precision patient recruitment solutions. These solutions aim to improve the accuracy, speed, and efficiency of identifying suitable patients for rare disease clinical trials, concurrently reducing recruitment timelines and enhancing trial success rates. A precision patient recruitment solution is a technology-driven method that utilizes advanced algorithms and real-world data to precisely identify and engage patients who meet specific clinical trial eligibility criteria. An example of this is Citeline PatientMatch, launched in April 2024 by Citeline, a US-based business intelligence and data analytics company. This platform combines sophisticated algorithms with comprehensive real-world data, including lab results, biomarkers, and electronic medical records from more than 400 hospitals and health systems, to assist sponsors and investigators in efficiently identifying eligible patients for clinical trials, streamlining enrollment, and accommodating diverse and complex study protocols across multiple therapeutic areas.
Who Are The Prominent Global Companies Shaping The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market?
Major companies operating in the artificial intelligence (AI)-driven rare disease patient finder market are UnitedHealth Group Incorporated, Dassault Systèmes SE, GeneDx Holdings Corp., HealthVerity Inc., ConcertAI Inc., Komodo Health Inc., Unlearn.AI Inc., Antidote Technologies Inc., Healx Ltd., FDNA Inc., Saventic Health Sp. z o.o., Digital Pharma Lab SAS, AnnieGuard Ltd., Rapid Innovation Labs Inc., Sqilline EOOD, TrialX Inc., enGenome Srl, EveryCure Inc., ThinkGenetic Inc., and RareSum Inc.
Download The Full Report For Exclusive Market Findings:
How Do Regional Market Performances Compare Within The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Industry?
North America was the largest region in the artificial intelligence (AI)-driven rare disease patient finder market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in artificial intelligence (AI)-driven rare disease patient finder report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Request A Customized Version Of The Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market Report:
https://www.thebusinessresearchcompany.com/customise?id=28129&type=smp
Browse Through More Reports Similar to the Global Artificial Intelligence (AI)-Driven Rare Disease Patient Finder Market 2025, By The Business Research Company
Artificial Intelligence In Healthcare Diagnosis Global Market Report 2025
Ai In Medical Diagnostics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/ai-in-medical-diagnostics-global-market-report
Artificial Intelligence Ai In Clinical Trials Global Market Report 2025
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
